Strategies to avoid compliance issues related to registries, space rentals, referral exchanges, waiver of copays, and EPSDT incentives.
Glenn S. Demby
Posts by the Author
Recent cases involve another fraud related to finger prick blood testing, as well as alleged malpractice and discrimination.
When structuring business arrangements, addressing six key risk areas can help laboratories avoid major compliance issues.
Though things appeared status quo in 2023, last year may prove to be a turning point for the laboratory industry.
An overview of the key 2023 mergers and acquisitions in the diagnostics industry and the trends they reveal.
G2’s list of major FDA approvals includes cancer and liquid biopsy, COVID-19, STI, and neurologic tests.
What 2023 Q3 earnings from 30 key US lab companies indicate about the current state of the industry and outlook for 2024.
Recent cases involve Medicare’s 14-Day Rule, improper PHI disclosure to a media outlet, kickbacks, and COVID-19 fraud.
First marketing authorization of a blood test assessing genetic variants related to cancer opens the door for clearance of similar tests.
With US STI cases continuing to climb to numbers not seen in decades, a recent FDA approval comes at an opportune moment.